Martin is Chair of Syncona Investment Management Ltd. He co-founded Syncona with the Wellcome Trust in 2012. Since then, Martin has been closely involved in the foundation and development of seven Syncona companies: Achilles Therapeutics, Autolus, OMass Therapeutics, Quell Therapeutics, Anaveon and Azeria Therapeutics. He was previously Chairman of former Syncona company Blue Earth Diagnostics, and before that, he was a partner at venture capital company MVM Life Science Partners LLP, leading their European operations. Martin has also held roles with 3i Group plc and McKinsey & Company. He has a PhD in Biochemistry from the University of Cambridge.
- Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual MeetingJune 5, 2023
- Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual MeetingJune 3, 2023
- Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual MeetingApril 18, 2023